Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
| General Information | |
| Organism | Homo sapiens, human |
| Cell Line Description | NCI-H23 is a human non-small cell lung cancer (NSCLC) cell line derived from a primary lung adenocarcinoma specimen obtained from a 51-year-old Black male patient. The cell line exhibits epithelial morphology and grows as an adherent monolayer under standard culture conditions. Cytogenetically, it displays an aneuploid karyotype characterized by numerical and structural chromosomal abnormalities. At the molecular level, NCI-H23 harbors key oncogenic driver mutations commonly found in aggressive NSCLC, including mutations in the KRAS (G12C) and TP53 genes, as well as inactivation of the LKB1/STK11 gene. Due to its well-defined genomic profile and robust growth characteristics, NCI-H23 has become a widely recognized in vitro model for investigating the pathogenesis of lung adenocarcinoma, exploring KRAS G12C signaling dynamics, evaluating novel targeted therapies and chemotherapeutic agents, and conducting high-throughput functional genomic screens. |
| Tissue | Lung |
| Disease | Lung Adenocarcinoma; Non-Small Cell Lung Cancer (NSCLC) |
| Morphology | Epithelial |
| Gender | Male |
| Age | 51 years |
| Product Format | Frozen |
| Growth Mode | Adherent |
| Biosafety Level | 1 (Biosafety classification is based on U.S. Public Health Service Guidelines) |
| Applications | 1. Research on the biology and oncogenic signaling pathways of non-small cell lung cancer (NSCLC); 2. In vitro evaluation of KRAS G12C-selective inhibitors and targeted chemotherapeutic agents; 3. Study of downstream signaling dynamics associated with STK11/LKB1 and TP53 co-mutations; 4. High-throughput screening of candidate drugs and functional genomic validation. |
| Shipped In | Dry ice |
| Storage Temperature | −196°C |
| Characteristics | |
| Karyotype | Aneuploid |
| Tumorigenic | Yes, tumorigenic in immunocompromised (nude) mice |
| Genetic Profile | KRAS mutation (G12C); TP53 mutation; STK11/LKB1 mutation |
| Mycoplasma Test | Negative |
| Culture Conditions and Handling | |
| Subculturing | 1. Remove and discard the culture medium. 2. Briefly rinse the cell monolayer with PBS (without Ca2+/Mg2+) to completely remove residual serum. 3. Add 1.0 to 2.0 mL of 0.25% trypsin-0.03% EDTA solution and incubate at 37°C until the cell monolayer detaches (typically 2 to 5 minutes). 4. Add fresh complete growth medium to neutralize the trypsin and gently pipette up and down to prepare a single-cell suspension. 5. Subculture the cell suspension into new culture vessels. |
| Medium Renewal | Every 2 to 3 days |
| Subcultivation Ratio | A split ratio of 1:3 to 1:6 is recommended |
| Culture Conditions | Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C |
| Cryopreservation | Complete growth medium supplemented with 5% to 10% (v/v) DMSO |
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RR0487 | Luciferase Reporter Cell Line - NCI-H23 | Inquiry |
| CSC-RO01627 | OVAL Stable Cell Line - NCI-H23 | Inquiry |
| CSC-RO01880 | GFP/OVAL Stable Cell Line - NCI-H23 | Inquiry |
| CSC-RO02133 | Luc/OVAL Stable Cell Line - NCI-H23 | Inquiry |
| CSC-RO02386 | GFP/Luc/OVAL Stable Cell Line - NCI-H23 | Inquiry |
The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.
Copyright © 2026 Creative Biogene. All rights reserved.